1. Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107. (3rd October 2022) Authors: Freeman, M; Bond, M; Murphy, B; Isaacsohn, J Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗